Scoggin Management’s AstraZeneca AZN Stock Holding History

Scoggin Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-184,532	Closed	-$13M	–	109
2014 Q4	$13M	Buy	184,532 +44,532	+32%	+$3.19M	1.18%	21
2014 Q3	$10M	Sell	140,000 -232,000	-62%	-$17M	0.53%	50
2014 Q2	$27.6M	Buy	+372,000	New	+$26.9M	1.63%	15

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Scoggin Management's AZN Position: Q1 2015 in Review

Scoggin Management sold out of AstraZeneca (AZN) in Q1 2015, closing a stake of 184,532 shares — an estimated $13M sold.

Scoggin Management first reported a position in AZN in Q2 2014 and held it in 3 quarters. The position peaked at $27.6M in Q2 2014. 385 funds tracked by Wall St. Rank hold AZN as of Q1 2015.

Scoggin Management reported no remaining AstraZeneca position as of Q1 2015 after selling out during the quarter.
Scoggin Management sold 184,532 AstraZeneca shares in Q1 2015, an estimated $13M.
Scoggin Management first reported a position in AstraZeneca in Q2 2014 and held it in 3 quarters.
Scoggin Management's AstraZeneca position peaked at $27.6M in Q2 2014.
385 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2015.

Based on Scoggin Management's 13F filing for Q1 2015, filed 15 May 2015.